04

Aug

EU says Novavax COVID shot must carry heart side-effect warning

(Reuters) - The European Medicines Agency (EMA) is recommending Novavax's COVID-19 vaccine carry a warning of the possibility of two types of heart inflammation, an added burden for a shot…

Read More Here

14

Feb

Germans pin hopes on Novavax moving the needle among anti-vaxxers

BERLIN, Feb 14 (Reuters) - Benedikt Richter, a 40-year-old teacher in the southwest German city of Kaiserslautern, long held out against getting vaccinated against COVID-19. He felt uneasy about the…

Read More Here

11

Feb

Novavax says COVID-19 shot 80% effective in adolescent study

Novavax Inc  said its two-dose vaccine was 80% effective against COVID-19 in a late-stage trial testing the shot in teens aged 12 to 17 years. The trial involved 2,247 adolescents…

Read More Here

20

Dec

EU regulator backs Novavax shot as region’s fifth COVID-19 vaccine

Dec 20 (Reuters) - The European Union's drug regulator on Monday approved use of the COVID-19 vaccine from U.S.-based Novavax in people 18 years and older, paving the way for…

Read More Here

14

Jun

Novavax COVID-19 vaccine shows 90.4% efficacy in late stage trial

Novavax Inc said on Monday its COVID-19 vaccine candidate showed 90.4% overall efficacy against the disease in a late-stage trial. The American biotechnology company Novavax announced on Monday that its…

Read More Here

06

May

Novavax vaccine shows 51% efficacy against South African variant, study finds

Novavax Inc's COVID-19 vaccine had efficacy of 51% against infections caused by the South African variant among people who were HIV negative, and 43% in a group that included people…

Read More Here

24

Apr

EU Commission sees potential in protein-based COVID-19 vaccines

Th EU Commission may eventually expand its portfolio of COVID-19 jabs to protein-based vaccines, the EU executive's President Ursula von der Leyen suggested on Friday. "We will certainly add other…

Read More Here

30

Mar

GSK to fill up to 60 million Novavax vaccine doses for Britain

GlaxoSmithKline has agreed in principle to handle the final part of the manufacturing process or up to 60 million doses of Novavax's COVID-19 vaccine for use in Britain, widening the company's role in the fight against the pandemic. GSK said in…

Read More Here

12

Mar

Novavax vaccine 96% effective against original coronavirus, 86% vs British variant in UK trial

Novavax Inc’s COVID-19 vaccine was 96% effective in preventing cases caused by the original version of the coronavirus in a late-stage trial conducted in the United Kingdom, the company said,…

Read More Here

11

Jan

EXCLUSIVE – EU seeks more Moderna COVID-19 vaccines, eyes deals with Valneva, Novavax

BRUSSELS/MILAN, Jan 11 (Reuters) - The European Union is in talks with Moderna to order more of its COVID-19 vaccine despite the company seeking a higher price, and is also…

Read More Here

25

Sep

Novavax initiates late-stage COVID-19 vaccine trial in UK

Novavax Inc on Thursday started a late-stage trial of its experimental COVID-19 vaccine in the United Kingdom in partnership with the government's Vaccines Taskforce, sending the company's shares up 6%…

Read More Here

24

Sep

EU close to concluding preliminary talks with Novavax on COVID vaccine supply

Brussels is close to wrapping up preliminary talks with U.S. vaccine maker Novavax for its potential COVID-19 shot, an EU source involved in the negotiations said, as the bloc ramps…

Read More Here

27

Aug

Novavax CEO expects filing for Covid-19 vaccine approval in December

Novavax Inc expects filing for approval of its COVID-19 vaccine candidate in the United States in December, Chief Executive Stanley Erck said in an interview for Czech daily Hospodarske Noviny,…

Read More Here